• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当代严重症状性主动脉瓣狭窄的处理方法。

Contemporary Management of Severe Symptomatic Aortic Stenosis.

机构信息

Cardiology Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.

Cardinal Wyszynski National Institute of Cardiology, Warsaw, Poland.

出版信息

J Am Coll Cardiol. 2021 Nov 30;78(22):2131-2143. doi: 10.1016/j.jacc.2021.09.864.

DOI:10.1016/j.jacc.2021.09.864
PMID:34823655
Abstract

BACKGROUND

There were gaps between guidelines and practice when surgery was the only treatment for aortic stenosis (AS).

OBJECTIVES

This study analyzed the decision to intervene in patients with severe AS in the EORP VHD (EURObservational Research Programme Valvular Heart Disease) II survey.

METHODS

Among 2,152 patients with severe AS, 1,271 patients with high-gradient AS who were symptomatic fulfilled a Class I recommendation for intervention according to the 2012 European Society of Cardiology guidelines; the primary end point was the decision for intervention.

RESULTS

A decision not to intervene was taken in 262 patients (20.6%). In multivariate analysis, the decision not to intervene was associated with older age (odds ratio [OR]: 1.34 per 10-year increase; 95% CI: 1.11 to 1.61; P = 0.002), New York Heart Association functional classes I and II versus III (OR: 1.63; 95% CI: 1.16 to 2.30; P = 0.005), higher age-adjusted Charlson comorbidity index (OR: 1.09 per 1-point increase; 95% CI: 1.01 to 1.17; P = 0.03), and a lower transaortic mean gradient (OR: 0.81 per 10-mm Hg decrease; 95% CI: 0.71 to 0.92; P < 0.001). During the study period, 346 patients (40.2%, median age 84 years, median EuroSCORE II [European System for Cardiac Operative Risk Evaluation II] 3.1%) underwent transcatheter intervention and 515 (59.8%, median age 69 years, median EuroSCORE II 1.5%) underwent surgery. A decision not to intervene versus intervention was associated with lower 6-month survival (87.4%; 95% CI: 82.0 to 91.3 vs 94.6%; 95% CI: 92.8 to 95.9; P < 0.001).

CONCLUSIONS

A decision not to intervene was taken in 1 in 5 patients with severe symptomatic AS despite a Class I recommendation for intervention and the decision was particularly associated with older age and combined comorbidities. Transcatheter intervention was extensively used in octogenarians.

摘要

背景

在主动脉瓣狭窄(AS)仅接受手术治疗的情况下,指南与实践之间存在差距。

目的

本研究分析了 EORP VHD(欧洲观察性研究计划瓣膜性心脏病)II 调查中严重 AS 患者介入治疗的决策。

方法

在 2152 名严重 AS 患者中,1271 名有高梯度 AS 的症状性患者根据 2012 年欧洲心脏病学会指南符合介入治疗 I 级推荐;主要终点是干预决策。

结果

262 名患者(20.6%)决定不进行干预。多变量分析显示,决定不干预与年龄较大(每增加 10 岁,比值比 [OR]:1.34;95%CI:1.11 至 1.61;P = 0.002)、纽约心脏协会功能分级 I 和 II 级与 III 级(OR:1.63;95%CI:1.16 至 2.30;P = 0.005)、较高的年龄调整 Charlson 合并症指数(OR:每增加 1 分,1.09;95%CI:1.01 至 1.17;P = 0.03)和较低的跨主动脉平均梯度(OR:每降低 10mmHg,0.81;95%CI:0.71 至 0.92;P<0.001)相关。在研究期间,346 名患者(40.2%,中位年龄 84 岁,中位 EuroSCORE II [欧洲心脏手术风险评估系统 II] 3.1%)接受了经导管介入治疗,515 名患者(59.8%,中位年龄 69 岁,中位 EuroSCORE II 1.5%)接受了手术。决定不干预与干预相比,6 个月生存率较低(87.4%;95%CI:82.0 至 91.3 与 94.6%;95%CI:92.8 至 95.9;P<0.001)。

结论

尽管有 I 级介入治疗推荐,但仍有 1/5 的严重有症状 AS 患者决定不进行干预,且该决定特别与年龄较大和合并症有关。经导管介入治疗在 80 岁以上人群中广泛应用。

相似文献

1
Contemporary Management of Severe Symptomatic Aortic Stenosis.当代严重症状性主动脉瓣狭窄的处理方法。
J Am Coll Cardiol. 2021 Nov 30;78(22):2131-2143. doi: 10.1016/j.jacc.2021.09.864.
2
Factors influencing the choice between transcatheter and surgical treatment of severe aortic stenosis in patients younger than 80 years: Results from the OBSERVANT study.影响 80 岁以下严重主动脉瓣狭窄患者经导管与手术治疗选择的因素:来自 OBSERVANT 研究的结果。
Catheter Cardiovasc Interv. 2020 May 1;95(6):E186-E195. doi: 10.1002/ccd.28447. Epub 2019 Aug 18.
3
Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey.当代瓣膜性心脏病的表现与处理:EURObservational Research Programme-Valvular Heart Disease II 调查。
Circulation. 2019 Oct;140(14):1156-1169. doi: 10.1161/CIRCULATIONAHA.119.041080. Epub 2019 Sep 12.
4
Transcatheter Aortic Valve Implantation in Patients With Paradoxical Low-Flow, Low-Gradient Aortic Stenosis.经导管主动脉瓣植入术治疗矛盾性低流量、低梯度主动脉瓣狭窄患者
Am J Cardiol. 2018 Aug 15;122(4):625-632. doi: 10.1016/j.amjcard.2018.04.044. Epub 2018 May 17.
5
Intervention Versus Observation in Symptomatic Patients With Normal Flow Low Gradient Severe Aortic Stenosis.症状性正常血流低梯度重度主动脉瓣狭窄患者的干预与观察。
JACC Cardiovasc Imaging. 2018 Sep;11(9):1225-1232. doi: 10.1016/j.jcmg.2017.07.020. Epub 2017 Oct 18.
6
Predictors of Mortality and Symptomatic Outcome of Patients With Low-Flow Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术治疗低流量重度主动脉瓣狭窄患者的死亡率和症状转归的预测因素。
J Am Heart Assoc. 2018 Apr 13;7(8):e007977. doi: 10.1161/JAHA.117.007977.
7
The impact of the development of transcatheter aortic valve implantation on the management of severe aortic stenosis in high-risk patients: treatment strategies and outcome.经导管主动脉瓣植入术的发展对高危患者严重主动脉瓣狭窄管理的影响:治疗策略与结果
Eur J Cardiothorac Surg. 2017 Jan;51(1):80-88. doi: 10.1093/ejcts/ezw211. Epub 2016 Aug 30.
8
Outcome prediction following transcatheter aortic valve implantation: Multiple risk scores comparison.经导管主动脉瓣植入术后的结局预测:多种风险评分比较
Cardiol J. 2016;23(2):169-77. doi: 10.5603/CJ.a2015.0081. Epub 2015 Dec 29.
9
Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis.自膨式经导管主动脉瓣系统用于有症状的高危重度主动脉瓣狭窄患者。
J Am Coll Cardiol. 2017 Dec 26;70(25):3127-3136. doi: 10.1016/j.jacc.2017.10.060.
10
Moderate aortic stenosis: culprit or bystander?中度主动脉瓣狭窄:罪魁祸首还是旁观者?
Open Heart. 2022 Jan;9(1). doi: 10.1136/openhrt-2021-001743.

引用本文的文献

1
A New Benchmark for Modern Management of Valvular Heart Disease: The Whole-Life Cycle Management System.心脏瓣膜病现代管理的新基准:全生命周期管理系统
JACC Asia. 2025 May;5(5):609-632. doi: 10.1016/j.jacasi.2025.01.017. Epub 2025 Apr 8.
2
Clonal Hematopoiesis Is Associated With Adverse Clinical Outcomes and Left Ventricular Remodeling in Aortic Stenosis.克隆性造血与主动脉瓣狭窄的不良临床结局及左心室重塑相关。
JACC Adv. 2025 Jan 8;4(2):101532. doi: 10.1016/j.jacadv.2024.101532. eCollection 2025 Feb.
3
Clinical Outcomes According to Aortic Stenosis Management: Insights From Real-World Practice.
临床结局与主动脉瓣狭窄管理:真实世界实践的启示。
J Am Heart Assoc. 2024 Nov 19;13(22):e036657. doi: 10.1161/JAHA.124.036657. Epub 2024 Nov 15.
4
Correlation between staging classification of aortic stenosis based on the extent of cardiac damage and platelet indices.基于心脏损伤程度的主动脉瓣狭窄分期分类与血小板指数的相关性。
BMC Cardiovasc Disord. 2024 Oct 14;24(1):555. doi: 10.1186/s12872-024-04246-7.
5
Treating Aortic Valve Stenosis for Vitality Improvement: The TAVI Study.治疗主动脉瓣狭窄以改善生活质量:经导管主动脉瓣置换术(TAVI)研究
Diseases. 2024 Aug 2;12(8):175. doi: 10.3390/diseases12080175.
6
Living in disadvantaged neighborhoods linked to less intervention for severe aortic stenosis.生活在不利社区与严重主动脉瓣狭窄的干预较少有关。
Sci Rep. 2024 Feb 28;14(1):4952. doi: 10.1038/s41598-024-52660-w.
7
Outcome of transcatheter aortic valve replacement in Israeli Jews and Arabs.以色列犹太人和阿拉伯人经导管主动脉瓣置换术的结果。
J Thorac Dis. 2024 Jan 30;16(1):241-246. doi: 10.21037/jtd-23-1391. Epub 2024 Jan 4.
8
Electrocardiography versus Echocardiography in Severe Aortic Stenosis with the Consideration of Coexistent Coronary Artery Disease.严重主动脉瓣狭窄合并冠状动脉疾病时心电图与超声心动图的对比研究
J Clin Med. 2024 Feb 9;13(4):1013. doi: 10.3390/jcm13041013.
9
Usefulness of the N-Terminal of the Prohormone Brain Natriuretic Peptide in Predicting Acute Kidney Injury Requiring Renal Replacement Therapy in Patients Undergoing Heart Valve Surgery.脑利钠肽原 N 端在预测心脏瓣膜手术后需要肾脏替代治疗的急性肾损伤中的作用。
Medicina (Kaunas). 2023 Nov 27;59(12):2083. doi: 10.3390/medicina59122083.
10
First description and validation of a new method for estimating aortic stenosis burden and predicting the functional response to TAVI.首次描述并验证一种用于评估主动脉瓣狭窄负荷及预测经导管主动脉瓣置入术(TAVI)功能反应的新方法。
Front Cardiovasc Med. 2023 Nov 14;10:1215826. doi: 10.3389/fcvm.2023.1215826. eCollection 2023.